135 related articles for article (PubMed ID: 23820386)
1. Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.
Pecchi S; Ni ZJ; Han W; Smith A; Lan J; Burger M; Merritt H; Wiesmann M; Chan J; Kaufman S; Knapp MS; Janssen J; Huh K; Voliva CF
Bioorg Med Chem Lett; 2013 Aug; 23(16):4652-6. PubMed ID: 23820386
[TBL] [Abstract][Full Text] [Related]
2. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis.
Kim O; Jeong Y; Lee H; Hong SS; Hong S
J Med Chem; 2011 Apr; 54(7):2455-66. PubMed ID: 21388141
[TBL] [Abstract][Full Text] [Related]
4. Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model.
Han W; Menezes DL; Xu Y; Knapp MS; Elling R; Burger MT; Ni ZJ; Smith A; Lan J; Williams TE; Verhagen J; Huh K; Merritt H; Chan J; Kaufman S; Voliva CF; Pecchi S
Bioorg Med Chem Lett; 2016 Feb; 26(3):742-746. PubMed ID: 26774655
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.
Staben ST; Siu M; Goldsmith R; Olivero AG; Do S; Burdick DJ; Heffron TP; Dotson J; Sutherlin DP; Zhu BY; Tsui V; Le H; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Sideris S; Wiesmann C; Wu P
Bioorg Med Chem Lett; 2011 Jul; 21(13):4054-8. PubMed ID: 21636270
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kβ Inhibitors.
Cao S; Cao R; Liu X; Luo X; Zhong W
Molecules; 2016 Jul; 21(7):. PubMed ID: 27384552
[TBL] [Abstract][Full Text] [Related]
7. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
[TBL] [Abstract][Full Text] [Related]
8. The Guareschi Pyridine Scaffold as a Valuable Platform for the Identification of Selective PI3K Inhibitors.
Galli U; Ciraolo E; Massarotti A; Margaria JP; Sorba G; Hirsch E; Tron GC
Molecules; 2015 Sep; 20(9):17275-87. PubMed ID: 26393561
[TBL] [Abstract][Full Text] [Related]
9. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Evaluation of Imidazo[1,2-a]pyridine Analogues of the ZSTK474 Class of Phosphatidylinositol 3-Kinase Inhibitors.
Gamage SA; Spicer JA; Tsang KY; O'Connor PD; Flanagan JU; Lee WJ; Dickson JMJ; Shepherd PR; Denny WA; Rewcastle GW
Chem Asian J; 2019 Apr; 14(8):1249-1261. PubMed ID: 30714356
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation.
Giordanetto F; Wållberg A; Cassel J; Ghosal S; Kossenjans M; Yuan ZQ; Wang X; Liang L
Bioorg Med Chem Lett; 2012 Nov; 22(21):6665-70. PubMed ID: 23010274
[TBL] [Abstract][Full Text] [Related]
12. Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase.
Staben ST; Blaquiere N; Tsui V; Kolesnikov A; Do S; Bradley EK; Dotson J; Goldsmith R; Heffron TP; Lesnick J; Lewis C; Murray J; Nonomiya J; Olivero AG; Pang J; Rouge L; Salphati L; Wei B; Wiesmann C; Wu P
Bioorg Med Chem Lett; 2013 Feb; 23(3):897-901. PubMed ID: 23265894
[TBL] [Abstract][Full Text] [Related]
13. Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.
Park H; Choi H; Hong S; Kim D; Oh DS; Hong S
Bioorg Med Chem Lett; 2011 Apr; 21(7):2021-4. PubMed ID: 21354792
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
15. Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies.
Gilbert AM; Nowak P; Brooijmans N; Bursavich MG; Dehnhardt C; Santos ED; Feldberg LR; Hollander I; Kim S; Lombardi S; Park K; Venkatesan AM; Mallon R
Bioorg Med Chem Lett; 2010 Jan; 20(2):636-9. PubMed ID: 19969455
[TBL] [Abstract][Full Text] [Related]
16. Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors.
Wang J; Wang X; Chen Y; Chen S; Chen G; Tong L; Meng L; Xie Y; Ding J; Yang C
Bioorg Med Chem Lett; 2012 Jan; 22(1):339-42. PubMed ID: 22130133
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kawaguchi K; Kaizawa H; Koizumi T; Ohishi T; Yamano M; Okada M; Ohta M; Tsukamoto S; Raynaud FI; Parker P; Workman P; Waterfield MD
Bioorg Med Chem; 2007 Sep; 15(17):5837-44. PubMed ID: 17601739
[TBL] [Abstract][Full Text] [Related]
18. Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.
Rice KD; Kim MH; Bussenius J; Anand NK; Blazey CM; Bowles OJ; Canne-Bannen L; Chan DS; Chen B; Co EW; Costanzo S; DeFina SC; Dubenko L; Engst S; Franzini M; Huang P; Jammalamadaka V; Khoury RG; Klein RR; Laird AD; Le DT; Mac MB; Matthews DJ; Markby D; Miller N; Nuss JM; Parks JJ; Tsang TH; Tsuhako AL; Wang Y; Xu W
Bioorg Med Chem Lett; 2012 Apr; 22(8):2693-7. PubMed ID: 22450127
[TBL] [Abstract][Full Text] [Related]
19. Discovery of new azaindole-based PI3Kα inhibitors: apoptotic and antiangiogenic effect on cancer cells.
Hong S; Lee S; Kim B; Lee H; Hong SS; Hong S
Bioorg Med Chem Lett; 2010 Dec; 20(24):7212-5. PubMed ID: 21067921
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.
Hamdouchi C; Zhong B; Mendoza J; Collins E; Jaramillo C; De Diego JE; Robertson D; Spencer CD; Anderson BD; Watkins SA; Zhang F; Brooks HB
Bioorg Med Chem Lett; 2005 Apr; 15(7):1943-7. PubMed ID: 15780638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
